In humans, VRL has been evaluated as a single-agent therapy in two nonrandomized studies in NSCLC patients without previous chemotherapy, and 23 out of 69 patients (33%) demonstrated a partial response [30]. This evidence concerns the gene TRPV2 and non-small cell lung carcinoma.